# Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis

> **NCT05077956** · — · WITHDRAWN · sponsor: **Providence Health & Services**

## Conditions studied

- Relapsing Multiple Sclerosis
- Multiple Sclerosis

## Interventions

- **DIAGNOSTIC_TEST:** Cerebrospinal and Blood Serum Semaphorin 4A Levels

## Key facts

- **NCT ID:** NCT05077956
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10-19
- **Primary completion:** 2023-10-25
- **Final completion:** 2023-10-25
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No participants were enrolled before closing the study
- **Last updated:** 2023-08-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05077956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05077956, "Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05077956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*